Zusammenfassung
Indikationen, Wirkungsweise, Nebenwirkungen und Risiken, Kontraindikationen und Interaktionen werden für die Antidementiva im allgemeinen Teil und dann für jedes Arzneimittel spezifisch im Präparateteil beschrieben.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Literatur
Alsubaie N, Al-Kuraishy HM, Al-Gareeb AI et al (2022) Statins use in Alzheimer disease: bane or boon from frantic search and narrative review. Brain Sci 12(10):1290
Bartels C, Wagner M, Wolfsgruber S et al (2018) Impact of SSRI Therapy on risk of conversion from mild cognitive impairment to Alzheimer’s dementia in individuals with previous depression. Am J Psychiatry 175(3):232–241
Battle CE, Abdul-Rahim AH, Shenkin SD et al (2021) Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis. Cochrane Database Syst Rev 2(2):CD13306
Bazzari FH, Bazzari AH (2022) BACE1 Inhibitors for Alzheimer’s disease: the past, present and any future? Molecules 27(24):8823
Christl J, Verhülsdonk S, Pessanha F et al (2019) Association of cerebrospinal fluid S100B protein with core biomarkers and cognitive deficits in prodromal and mild Alzheimer’s disease. J Alzheimers Dis 4:1119–1127
Coupland CAC, Hill T, Dening T et al (2019) Anticholinergic drug exposure and the risk of dementia: a nested case-control study. JAMA Intern Med 179(8):1084–1093
DGN, DGPPN (2016) S3-Leitlinie „Demenzen“. https://register.awmf.org/assets/guidelines/038-013l_S3-Demenzen-2016-07.pdf. Zugegriffen: 29. Mai 2023
Glans I, Sonestedt E, Nägga K et al (2023) Association between dietary habits in midlife with dementia incidence over a 20-year period. Neurology 100(1):e28–e37
Haeberlein BS, Aisen PS, Barkhof F et al (2022) Two randomized phase 3 studies of aducanumab in early Alzheimer’s disease. J Prev Alzheimers Dis 9(2):197–210
Honig LS, Barakos J, Dhadda S et al (2023) ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer’s disease. Alzheimers Dement 9(1):e12377
Huang LK, Chao SP, Hu CJ (2020) Clinical trials of new drugs for Alzheimer disease. J Biomed Sci 27(1):18
Jack CR Jr, Bennett DA, Blennow K et al (2018) Toward a biological definition of Alzheimer’s disease. Alzheimers Dement 14(4):535–562
Klein G, Scelsi MA, Barakos J et al (2022) Comparing ARIA-E severity scales and effects of treatment management thresholds. Alzheimers Dement 14(1):e12376
Kuller LH, Lopez OL (2021) ENGAGE and EMERGE: truth and consequences? Alzheimers Dement 17(4):692–695
Lange-Asschenfeldt C (2013) Vaskuläre Faktoren in der Pathogenese der Alzheimer-Krankheit. Nervenarzt 84(6):732–737
Lee J, Howard RS, Schneider LS (2022) The current landscape of prevention trials in dementia. Neurotherapeutics 19(1):228–247
Liu YH, Chen Y, Wang QH et al (2022) One-year trajectory of cognitive changes in older survivors of COVID-19 in Wuhan, China: a longitudinal cohort study. JAMA Neurol 79(5):509–517
Lockery JE, Broder JC, Ryan J et al (2021) A cohort study of anticholinergic medication burden and incident dementia and stroke in older adults. J Gen Intern Med 36(6):1629–1637
McKeith IG, Boeve BF, Dickson DW et al (2017) Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology 89(1):88–100
Mintzer J, Lanctôt KL, Scherer RW et al (2021) Effect of methylphenidate on apathy in patients with Alzheimer disease: The ADMET 2 Randomized Clinical Trial. JAMA Neurol 78(11):1324–1332
Nelson PT, Dickson DW, Trojanowski JQ et al (2019) Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain 142(6):1503–1527
Orgeta V, Tabet N, Nilforooshan R, Howard R (2017) Efficacy of antidepressants for depression in Alzheimer’s disease: systematic review and meta-analysis. J Alzheimers Dis 58(3):725–733
Ossenkoppele R, Pichet Binette A et al (2022) Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nat Med 28(11):2381–2387
Palmqvist S, Stomrud E, Cullen N et al (2022) An accurate fully automated panel of plasma biomarkers for Alzheimer’s disease. Alzheimers Dement 19(4):1204–1215
Pyne JD, Brickman AM (2021) The impact of the COVID-19 pandemic on dementia risk: potential pathways to cognitive decline. Neurodegener Dis 21(1–2):1–23
Reiken S, Sittenfeld L, Dridi H et al (2022) Alzheimer’s-like signaling in brains of COVID-19 patients. Alzheimers Dement 18(5):955–965
Reish NJ, Jamshidi P, Stamm B et al (2023) Multiple cerebral hemorrhages in a patient receiving lecanemab and treated with t-PA for stroke. N Engl J Med 388(5):478–479
Reyes-Bueno JA, Mena-Vázquez N, Ojea-Ortega T et al (2020) Case fatality of COVID-19 in patients with neurodegenerative dementia. Neurologia 35(9):639–645
Ruthirakuhan M, Ismail Z, Herrmann N et al (2022) Mild behavioral impairment is associated with progression to Alzheimer’s disease: a clinicopathological study. Alzheimers Dement 18(11):2199–2208
Smith R, Wibom M, Pawlik D et al (2019) Correlation of in vivo [18F]flortaucipir with postmortem Alzheimer disease tau pathology. JAMA Neurol 76(3):310–317
Sondergaard KB, Weeke P, Wissenberg M et al (2017) Non-steroidal anti-inflammatory drug use is associated with increased risk of out-of-hospital cardiac arrest: a nationwide case-time-control study. Eur Heart J Cardiovasc Pharmacother 3(2):100–107
Tan MS, Yu JT, Tan CC et al (2015) Efficacy and adverse effects of ginkgo biloba for cognitive impairment and dementia: a systematic review and meta-analysis. J Alzheimers Dis 43(2):589–603
Tsoi KK, Chan JY, Chan FC et al (2019) Monotherapy is good enough for patients with mild-to-moderate Alzheimer’s disease: a network meta-analysis of 76 randomized controlled trials. Clin Pharmacol Ther 105(1):121–130
van Dyck CH, Swanson CJ, Aisen P et al (2023) Lecanemab in early Alzheimer’s disease. N Engl J Med 388(1):9–21
Vaz M, Silva V, Monteiro C et al (2022) Role of aducanumab in the treatment of Alzheimer’s disease: challenges and opportunities. Clin Interv Aging 17:797–810
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature
About this chapter
Cite this chapter
Lange-Asschenfeldt, C., Benkert, O. (2023). Antidementiva. In: Benkert, O., Hippius, H. (eds) Kompendium der Psychiatrischen Pharmakotherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-67685-1_6
Download citation
DOI: https://doi.org/10.1007/978-3-662-67685-1_6
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-67684-4
Online ISBN: 978-3-662-67685-1
eBook Packages: Medicine (German Language)